Founded in 2019, JLS Fund is a unique venture capital fund focused primarily on neuroscience, mental health and enabling tools and infrastructure. From Pre-seed and Seed investing to Series A and later-stage secondaries transitioning to buyout.
Mental health company dedicated to providing access to safe and affordable psychedelic-assisted therapy, beginning with ketamine therapy.
A clinical-stage neuroscience biotech transforming the treatment paradigm of psychiatric diseases.
A life science company focused on mushroom derived medicines.
MindMed discovers and develops psychedelics inspired medicine.
Biotechnology company developing psychedelic entities for treating addiction.
Reimagines psychoactive natural products as the building blocks for the next generation of neurological products
Mindful Capital Investing: Investing in the Future of Psychedelic Medicine
December 2-5, 2025
As psychedelic startups emerge and public companies go through market corrections, investors must distinguish hype from substance. This panel evaluates financial opportunities, timelines, and ESG considerations in the psychedelic sector.
Aspen Neuroscience closes Series C. Who took a piece of this $115 financing round? Find out here!
Check Out Our Substack!
.png){kind=small}
